Navigation Links
Linaclotide in Medical News

Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide

- Data to be presented at Digestive Disease Week 2009 - CAMBRIDGE, Mass. and NEW YORK, May 12, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced they will be reporting additional clinical data from their Phase 2b studies...

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

...nic constipation and shortly, we expect to begin Phase III trials for the additional indication of constipation predominant irritable bowel syndrome. linaclotide is a promising novel compound that may offer a much needed therapy for this very large and underserved patient population. Later this year we anticip...

Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80

... clinical results for three other late-stage pipeline products; aclidinium, linaclotide and cariprazine. Regarding aclidinium, we reported positive Phase III ACCLA...anuary 2009, following the initiation of the Phase III clinical program for linaclotide for the treatment of chronic constipation in September. Lastly, we reported...

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

...obstructive pulmonary disease; ceftaroline for serious hospital infections; linaclotide for the treatment of chronic constipation and constipation predominant irri...o submit to the FDA for review and reported positive Phase II-B results for linaclotide in the treatment of both chronic constipation and irritable bowel syndrome....
Linaclotide in Medical Technology

Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits -- CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced r...

Ironwood Announces Linaclotide European Licensing Agreement with Almirall

- Ironwood Will Receive Up To $55 Million in Near Term Payments - CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European rights to develop and commerciali...

Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

- Data Presented Today at ACG Annual Scientific Meeting - ORLANDO, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX ) today announced the presentation of results from a Phase 2b study assessing lina...

Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3

CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced it has raised $50 million in a private equity financing. This capital will be utilized to support the ongoing Phase 3 development program evaluating linaclotide for the treatment of irritable bowel syndrome...

Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

- Comprehensive Phase 3 Clinical Program Initiated - CAMBRIDGE, Mass. and NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE: FRX ) today announced they will present results of a Phase 2b study investigating ...

Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass. and NEW YORK, May 20 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE: FRX ) today announced the presentation of data from a Phase 2b randomi...

Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies

- Chronic constipation and IBS-C studies each meet primary endpoint - CAMBRIDGE, MASS. and NEW YORK, March 4 /PRNewswire-FirstCall/ -- Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX ) today announced positive top-line results from two Phase 2b randomized, double-blind, placebo-contr...

Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide

- Data being presented today at Digestive Disease Week - CAMBRIDGE, Mass., May 21, 2007 /PRNewswire/ -- Microbia today announced the presentation of data from a Phase 2 study in which linaclotide accelerated colonic transit and improved bowel function in patients with constipation- predominant irr...

Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain

...ar cGMP levels by stimulating guanylate cyclase C. linaclotide is currently being evaluated in a comprehensive Ph...rders. In a Phase 2b study in patients with IBS-C, linaclotide reduced abdominal pain and improved bowel habits. ... pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D.,...
Linaclotide in Biological Technology

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

CAMBRIDGE, Mass. and NEW YORK, Sept. 17 /PRNewswire-FirstCall/ -- Microbia, Inc. and Forest Laboratories, Inc. (NYSE: FRX ), today announced that they have entered into a 50/50 partnership in the United States to co-develop and co-market Microbia's first-in-class compound linaclotide. Linaclo...
Other Tags
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... OncLive proudly announces the 2015 Giants of ... a panel of eminent oncologists for landmark achievements that ... be introduced and celebrated TONIGHT at the 3rd Annual ... CDT at The Chicago Illuminating Company, 2110 S. Wabash ... groundbreaking accomplishments, in fields including translational research, gene therapy, ...
(Date:5/29/2015)... 2015 The report “Muscle Spasm ... on the therapeutic development for Muscle Spasm. Spasms ... the body, leading to many different symptoms and ... new targets and MOAs to produce first-in-class and ... review of Axillary Hyperhidrosis with 19 market data ...
(Date:5/29/2015)... AL (PRWEB) May 29, 2015 ... Fibromyalgia and Chronic Fatigue Syndrome is now offering ... Callers can learn about natural ways to reduce ... low moods, poor sleep, and brain fog. ... weekly Treating and Beating Fibromyalgia call in teleconferences ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3
Other Contents